Dedicated to the pursuit of justice


The pharmaceutical and medical device attorneys at CaseyGerry are currently accepting cases related to the anticoagulation drug dabigatran, sold under the brand name Pradaxa. Pradaxa is the leading alternative treatment to warfarin for non-valvular atrial fibrillation, the most common type of heart rhythm abnormality. A safety announcement released in December 2011 by the U.S. Food and Drug Association (FDA) indicates that patients who use Pradaxa may be at risk for serious and sometimes fatal bleeding. As reported in Reuters the manufacturer of Pradaxa, Boehringer Ingelheim, related 260 fatal bleeding deaths to the drug as of November 2011.
A study recently performed by researchers at the Cleveland Clinic looked at more than thirty thousand patients and found that patients who are taking Pradaxa have an up to 33% increase risk of heart attack or acute coronary syndrome than those taking warfarin.

The FDA warns that discontinuing the use of Pradaxa can put patients at greater risk for a stroke. However, you are encouraged to seek professional care immediately if you notice the following symptoms: uncontrolled or unusual bleeding, suspicious bruising, blood in urine or stool, or coughing or vomiting blood.

If you believe that you or a loved one may have been injured as the result of taking Pradaxa, the attorneys at CaseyGerry can help. Contact us today for a free consultation and case review.

Free Consultation

  • Required
  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.